Poor earnings took many stocks lower Tuesday.
News & Analysis: Myriad Genetics
The genetic-testing leader just whacked its fiscal full-year 2020 guidance.
Hardly anything went right for the genetic testing company in its fiscal 2020 Q1.
MYGN earnings call for the period ending September 30, 2019.
The genetic-testing stock can't seem to escape the trap of volatility.
Find out why these stocks held up well on a negative day for the markets.
The genetic testing leader took investors on a wild ride last month.
Cancer is one of the toughest diseases to fight, and these companies are playing a great role in helping people combat it.
A sluggish end to fiscal 2019 and weaker-than-expected guidance for the year ahead aren't instilling much confidence in investors.
Different challenges hit these companies but led to the same result.